Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-20 | 2024-03 | -0.37 | N/A | N/A | N/A |
2024-04-01 | 2023-12 | -0.52 | -1.06 | -0.54 | -103.85% |
2023-11-14 | 2023-09 | 0 | -0.57 | N/A | N/A |
2023-08-14 | 2023-06 | -0.45 | -0.69 | -0.24 | -53.33% |
2023-05-15 | 2023-03 | -0.85 | -0.81 | 0.04 | 4.71% |
2023-03-30 | 2022-12 | 0 | -0.73 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-05-16 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
2023-03-30 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-30 | JMP Securities | Upgrade | Market Outperform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2020-12-16 | APPLEBAUM SCOTT | Officer | 365.20K | Stock Award(Grant) |
2023-12-13 | BOURDOW CARRIE L | Chief Executive Officer | 642.92K | Stock Award(Grant) |
2023-12-13 | DEMITRACK MARK A | Officer | 306.22K | Stock Award(Grant) |
2023-12-13 | DRAKE PATRICIA M | Officer | 107.08K | Stock Award(Grant) |
2019-01-31 | GOWEN MAXINE | Chief Executive Officer | 470.01K | Purchase |
2018-03-21 | HABIB YACOUB PH.D. | Officer | 0.00 | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Renaissance Technologies, LLC | 182.15K | 160.48K | 1.33% |
2023-06-29 | Blackrock Inc. | 112.17K | 98.82K | 0.82% |
2023-06-29 | Vanguard Group Inc | 72.81K | 64.15K | 0.53% |
2023-06-29 | Geode Capital Management, LLC | 65.17K | 57.41K | 0.48% |
2023-06-29 | Simplex Trading, LLC | 37.59K | 33.12K | 0.27% |
2023-06-29 | Captrust Financial Advisors | 33.08K | 29.14K | 0.24% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Extended Market Index Fund | 70.18K | 61.83K | 0.51% |
2023-05-30 | Fidelity Extended Market Index Fund | 33.10K | 37.73K | 0.24% |
2023-08-30 | Fidelity OTC Portfolio | 17.81K | 15.49K | 0.13% |
2023-05-30 | Fidelity Total Market Index Fund | 8.95K | 10.20K | 0.07% |
2023-05-30 | Fidelity NASDAQ Composite Index Fund | 7.46K | 8.50K | 0.05% |
2023-05-30 | Fidelity Series Total Market Index Fund | 7.36K | 8.39K | 0.05% |
Split | Date |
---|---|
1 : 25 | 2022-11-10 |
-
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for $1.0 billion upfront -- PTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy half of rest of royalty for up to $250 million -- Transaction expected to enhance long-term Adjusted Cash Receipts growth (non-GAAP) -- Royalty Pharma to host conference call today, Thursday, October 19 at 9:00am EDT NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
-
-
-
Hope you learn your lesson and never sell Trevena!
-
$TRVN. I’ve got a buy ,one of many, back on 10/07/20 @ 3.16 how would you describe that…incautiously optimistic?
-
-
-
I’m holding for $10+
-
-
-
-
-
-
-
Back to $2
-
-
5 Hot Penny Stocks To Watch With Big News This Week
pennystocks.com • -
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023
globenewswire.com • -
Momentum Trading With Penny Stocks: Quick Guide
pennystocks.com • -
Best Penny Stocks To Buy Now? 4 To Watch Before May CPI Data
pennystocks.com • -
Why Is Trevena (TRVN) Stock Up 165% Today?
investorplace.com • -
Trevena to Participate in Three Upcoming Conferences
globenewswire.com • -
Trevena, Inc. (TRVN) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
Trevena, Inc. (TRVN) Q3 2022 Results - Earnings Call Transcript
seekingalpha.com • -
Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022
globenewswire.com • -
What Makes Trevena (TRVN) a New Buy Stock
zacks.com • -
Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022
globenewswire.com • -
Best Penny Stocks to Buy Next Week? 3 to Watch?
pennystocks.com • -
Trevena to Present at the H.C. Wainwright Global Investment Conference
globenewswire.com • -
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
globenewswire.com • -
Trevena Offers An Enticing Risk-Reward At These Prices
seekingalpha.com • -
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
globenewswire.com • -
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
pennystocks.com • -
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
globenewswire.com • -
New Strong Sell Stocks for August 20th
zacks.com • -
Trevena: Remaining Patient After A Disappointing Q2 Earnings
seekingalpha.com • -
Trevena: Q2 Earnings Insights
benzinga.com • -
Trevena Reports Second Quarter 2021 Results
globenewswire.com • -
Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021
globenewswire.com • -
Trevena's OLINVYK Provides One Of The Most Compelling Growth Profiles
seekingalpha.com • -
Trevena: Taking A Systematic Approach With A Speculative Investment
seekingalpha.com • -
TRVN Stock: Over 5% Increase Pre-Market Explanation
pulse2.com • -
TRVN Stock: Over 30% Increase Explanation
pulse2.com • -
2 Best Reddit Healthcare Stocks to Buy Now
fool.com • -
Moving Average Crossover Alert: Trevena (TRVN)
zacks.com • -
Trevena's Catalyst-Filled Q1
seekingalpha.com • -
Trevena: Reaffirming A Buy On OLINVYK DEA Scheduling
seekingalpha.com • -
Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (oliceridine) injection
globenewswire.com •